Sigyn Therapeutics, Inc. (OTCQB: SIGY) released a shareholder update on March 13, 2026, authored by CEO Jim Joyce, detailing the company's strategic initiatives including a potential merger with a Nasdaq-listed company and the sale of certain assets. The update comes after the company failed to execute an uplist to Nasdaq due to regulatory hurdles, prompting a shift in strategy to preserve shareholder value.
Joyce, who previously founded Aethlon Medical and developed the FDA-designated Hemopurifier, emphasized the potential of Sigyn's CardioDialysis therapy. The device targets cholesterol-transporting lipoproteins and inflammatory molecules, and is designed for use on dialysis machines available at over 7,500 clinics in the U.S., unlike limited lipoprotein apheresis centers. CardioDialysis aims to reduce major adverse cardiovascular events (MACE) more effectively than drugs, addressing the leading cause of death worldwide.
Beyond cardiovascular disease, CardioDialysis has shown promise in treating sepsis, for which there is no approved therapy. Joyce noted that the PMX hemoadsorption device, developed by Spectral Medical (TSX), is a leading candidate and encouraged shareholders to follow its progress. Sigyn's technology has been validated to reduce sepsis-inducing bacterial toxins and inflammatory mediators. Additionally, the company sees potential in treating traumatic brain injury (TBI) through systemic inflammation reduction, an asset it hopes to leverage in strategic transactions.
Joyce explained that Sigyn became public via a merger with an OTC company, similar to his previous experience with Aethlon Medical. However, a planned Nasdaq uplist financing fell through due to a catch-22: Nasdaq required investor review before SEC approval of the registration statement, while SEC wanted Nasdaq listing approval first. This led to the withdrawal of the registration statement. Joyce stated, "It was not anticipated that Nasdaq would request to review and approve our investors prior to obtaining an effective registration statement from SEC."
Despite these challenges, Joyce remains focused on advancing the company's therapies. The shareholder update references a previous January 15th communication outlining strategies to reduce shareholder dilution, including asset sales and a potential merger with a Nasdaq-listed company at risk of not meeting the $5 million minimum market value of listed securities (MVLS) requirement. Joyce also disclosed that as of March 11, 2026, Sigyn has 2,330,042 shares outstanding.
For more details, shareholders are directed to the full update at Sigyn Therapeutics Shareholder Update. The company's pipeline also includes ImmunePrep for immunotherapeutic antibody delivery, ChemoPrep for targeted chemotherapy, and ChemoPure to reduce chemotherapy toxicity.
